Cite
MLA Citation
Thomas Powles et al.. “Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.” Lancet oncology, vol. 21, no. 12, 2020, pp. 1574–1588. http://access.bl.uk/ark:/81055/vdc_100115297263.0x000014